Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
NCT01279798 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2011-03-01
Summary
This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03. A total of 45 patients will be enrolled into the study.
Conditions
Interventions
- BIOLOGICAL
-
Lucanix® (belagenpumatucel-L)
Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
Sponsors & Collaborators
-
NovaRx Corporation
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
NCT00130780 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
NCT01297491 ·Status: COMPLETED ·Phase: PHASE2
-
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
NCT03780010 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NCT00073398 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
NCT00418743 ·Status: UNKNOWN
-
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
NCT02204345 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Participants With Advanced Non-Small Cell Lung Cancer
NCT00948675 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
NCT05619744 ·Status: COMPLETED ·Phase: PHASE1
-
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
NCT03779191 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
NCT04274907 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT01496742 ·Status: COMPLETED ·Phase: PHASE2
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
NCT00741988 ·Status: COMPLETED ·Phase: PHASE2
-
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
NCT02328105 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00334763 ·Status: TERMINATED ·Phase: PHASE2
-
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
NCT01814163 ·Status: COMPLETED
-
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02546986 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
NCT00762034 ·Status: COMPLETED ·Phase: PHASE3
-
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT03845296 ·Status: COMPLETED ·Phase: PHASE2
-
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
NCT04227028 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC
NCT03526887 ·Status: COMPLETED ·Phase: PHASE2
-
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
NCT03157089 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
NCT05132413 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
NCT02007070 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817 ·Status: RECRUITING ·Phase: PHASE1/PHASE2